Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
aminopterin · 1 trial · 1 indication
| Name | Type | Description |
|---|---|---|
| aminopterin | DRUG | - |
| leucovorin calcium | DRUG | - |
DISEASE CHARACTERISTICS: Histologically proven acute leukemia of any histologic type that is refractory to known effective therapy PATIENT CHARACTERISTICS: Age: Any age Performance status: Karnofsky 50-100% Life expectancy: At least 6 weeks Hematopoietic: Not specified Hepatic: Bilirubin no greater...
Top 20 of 60 competitors
Aminopterin is an investigational small molecule being studied for the treatment of leukemia. It is a folate antagonist that has been evaluated in patients with refractory leukemia, meaning leukemia that has not responded to prior treatment. The drug is in Phase 2 clinical development and is not yet approved by regulatory authorities.
Aminopterin is being developed by Sanofi, a global biopharmaceutical company. Sanofi's stock is traded under the ticker symbol SNY. The company is conducting clinical research on aminopterin as a potential treatment for leukemia, though the drug remains investigational and has not received regulatory approval.
Aminopterin is in Phase 2 clinical development for the treatment of leukemia. It has completed one Phase 2 clinical trial, and the drug is still considered investigational. Aminopterin has not been approved by the FDA or any other regulatory agency, and its safety and efficacy have not been fully established.
Aminopterin has been studied in one completed Phase 2 clinical trial, identified as NCT00003305. This trial, titled 'Aminopterin in Treating Patients With Refractory Leukemia,' enrolled 75 participants in the United States. The study was uncontrolled, meaning there was no comparison group, and it evaluated the drug's effects in patients with refractory leukemia.
Aminopterin is a folate antagonist, which means it interferes with the action of folic acid, a vitamin essential for DNA synthesis and cell division. By blocking folate metabolism, aminopterin can inhibit the growth of rapidly dividing cells, such as leukemia cells. This mechanism is the basis for its potential use in cancer treatment.